Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Clinical trial NCT03643107 · COMPLETED

Trial details

NCT number: NCT03643107
Sponsor: Allarity Therapeutics
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Castration-Resistant Prostate Cancer Patients

Start date: 2018-10-17
Primary completion: 2021-10-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.